The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis

Cytokine

Volumn 33, Issue 2, 2006, Pages 106-110

  Litinsky, Irena ^a,b   Paran, Daphna ^a,b   Levartovsky, David ^a,b   Wigler, Irena ^a,b   Kaufman, Ilana ^a,b   Yaron, Ilana ^a,b   Yaron, Michael ^a,b   Caspi, Dan ^a,b   Elkayam, Ori ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cytokines; Leflunomide; Metalloproteinases; Rheumatoid arthritis

Indexed keywords

AMINOTRANSFERASE; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LEFLUNOMIDE; PREDNISONE; STROMELYSIN;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; JOINT STIFFNESS; JOINT SWELLING; MALE; PARESTHESIA; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VISUAL ANALOG SCALE; VOMITING;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; ISOXAZOLES; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MIDDLE AGED;

EID: 33644988939     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2005.12.009     Document Type: Article

References (34)

1. G.S. Alarcon Epidemiology of rheumatoid arthritis Rheum Dis Clin North Am 21 1995 589 604
2. E.M. Gravallese Bone destruction in arthritis Ann Rheum Dis 61 2002 284 286
3. M. Bromley, and D.E. Wooley Histopathology of the rheumatoid lesion. Identification of cell types at sites of cartilage erosion Arthritis Rheum 27 8 1984 857 863
4. T.J. Smeets, M.C. Kraan, S. Galjaard, P.P. Yossef, M.D. Smith, and P.P. Tak Analysis of cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial specimens from the cartilage-pannus function in patients with RA Ann Rheum Dis 60 6 2001 561 565
5. C. Ribbens, M. Martin y Porras, N. Frachimont, M.J. Kaiser, J.M. Jaspar, and P. Damas Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment Ann Rheum Dis 61 2 2002 161 166
6. E.H. Choy, and G.S. Panayi Cytokine pathways and joint inflammation in rheumatoid arthritis N Engl J Med 344 2001 907 916
7. M.J. Kaplan Leflunomide Aventis Pharma Curr Opin Investig Drugs 2 2001 222 230
8. K. Silva, and R.E. Morris Leflunomide and malononitrilamides Am J Med Sci 313 1997 289 301
9. J.P. Davis, G.A. Cain, W.J. Pitts, R.L. Magolda, and R.A. Copeland The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase Biochemistry 35 1996 1270 1273
10. W. Knecht, U. Bergiohann, B. Kitshbaum, and M. Loeffler Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme Eur J Biochem 240 1996 292 302
11. X. Xu, J.W. Williams, H. Gong, A. Finnegan, and A.S.F. Chong Two activities of the immunosuppressive metabolite of leflunomide, A77-1726: inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation Biochem Pharmacol 52 1996 527 534
12. T. Mattar, K. Kochhar, R. Barlett, E.G. Bremer, and A. Finnegan Inhibition of the epidermal growth receptor tyrosine kinase activity by leflunomide FEBS Lett 334 1993 161 164
13. R.R. Barlett, H. Anagnostopulos, T. Zielinsky, T. Mattar, and R. Schleyerbach Effects of leflunomide on immune responses and models of inflammation Springer Semin Immunopathol 14 1993 381
14. M.C. Kraan, R.J. Reece, E.C. Barg, T.J. Smeets, J. Farnell, and R. Rosenburg Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis Arthritis Rheum 43 2000 1820 1830
15. D.T. Felson, J.J. Anderson, M. Boers, C. Bombardier, D. Furst, and C. Goldsmith American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 1995 727 735
16. R.I. Fox, M.L. Hermann, C.G. Frangou, G.M. Wahl, R.E. Morris, and V. Strand Mechanism of action for leflunomide in rheumatoid arthritis Clin Immunol 93 1999 198 208
17. F.C. Breedveld, and J.M. Dayer Leflunomide: mode of action in the treatment of rheumatoid arthritis Ann Rheum Dis 59 2000 841 849
18. D.E. Furst Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors Rheumatology 38 Suppl. 2 1999 14 18
19. J.S. Smolen, J.R. Kalden, D.L. Scott, B. Rozman, T.K. Kvein, and A. Larsen Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial. European leflunomide study group Lancet 353 1999 259 266
20. V. Strand, S. Cohen, M. Schiff, A. Weaver, R. Fleischmann, and G. Cannon Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide rheumatoid arthritis investigators group Arch Intern Med 159 1999 2542 2550
21. P. Emery, F.C. Breedveld, E.M. Lemmel, J.P. Kaltwasser, P.T. Dawes, and B. Gomor A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis Rheumatology 39 2000 655 665
22. J.R. Kalden, D.L. Scott, J.S. Smolen, M. Schattenkirchener, B. Rozman, and B.D. Williams Improved functional ability in patients with rheumatoid arthritis - long-term treatment with leflunomide versus sulfasalazine. European leflunomide study group J Rheumatol 29 2002 205
23. P. Geborek, M. Crnkic, I.F. Petersson, and T. Saxne Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden Ann Rheum Dis 61 2002 793 798
24. G. Keyszer, I. Lambiri, R. Nagel, C. Keysser, M. Keysser, and E. Gromnica-Ihle Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1(TIMP-1) and MMP-1/TIMP-1 complex in rheumatic disease: correlation with clinical activity of rheumatoid arthritis versus other surrogate markers J Rheumatol 26 1999 251
25. M.J. Green, A.K. Gough, J. Devlin, J. Smith, P. Astin, and D. Taylor Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis Rheumatology (Oxford) 42 2003 83 88
26. O. Elkayam, I. Yaron, I. Shirazi, R. Judovitch, D. Caspi, and M. Yaron Active leflunomide metabolite inhibits interleukin 1beta, tumor necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures Ann Rheum Dis 62 2003 440 443
27. D. Burger, N. Begue-Pator, S. Benavet, L. Grauz, M.T. Kaufmann, and R. Chiccheportiche The active metabolite of leflunomide, A77 1727, inhibits the production of prostaglandin E2, matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes Rheumatology (Oxford) 42 2003 89 96
28. G. Palmer, D. Burger, F. Mezin, D. Magne, C. Gabay, and J.M. Dayer The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes Arthritis Res Ther 6 2004 R181 R189
29. M. Cutolo, A. Sulli, P. Ghiorzo, C. Pizzorni, C. Craviotto, and B. Villaggio Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis Ann Rheum Dis 62 2003 297 302
30. P.K. Wong, I.K. Campbell, P.J. Egan, M. Ernst, and I.P. Wicks The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover Arthritis Rheum 48 5 2003 1177 1189
31. E.H. Choy, D.A. Isenberg, T. Garrood, S. Farrow, Y. Ioannou, and H. Bird Therapeutic benefit of blocking interleukin-6 activity with anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, blind, placebo-controlled, dose-escalation trial Arthritis Rheum 46 12 2002 3143 3150
32. K. Asadullah, W. Sterry, and H.D. Volk Interleukin-10 therapy - review of a new approach Pharmacol Rev 55 2 2003 241 269
33. P. Charles, M.J. Elliot, D. Davis, A. Potter, J.R. Kalden, and C. Antoni Regulation of cytokines, cytokine inhibitors, and acute phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis J Immunol 163 3 1999 1521 1528
34. D. Nowak, J. Lewandowicz, B. Dbkowska, and J. Marczak Combination of methotrexate and prednisone decreases circulating concentrations of interleukin-1 beta and interleukin-6 in patients with rheumatoid arthritis. Poor correlation of cytokine suppression with clinical improvement Int J Immunopathol Pharmacol 12 1 1999 13 21